SERPINA1 11478G → A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD

Thorax

Volumn 66, Issue 5, 2011, Pages 418-424

  Quint, Jennifer K ^a   Donaldson, Gavin C ^a   Kumari, Meena ^a   Talmud, Philippa J ^a   Hurst, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; INTERLEUKIN 6;

ADULT; ALLELE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA POLYMORPHISM; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; UPREGULATION;

EID: 79954994717     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.152975     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease Updated 2007. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2= 1&intId=989 (accessed 7 Sep. 2010).
2. Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 2006;61:164-8.
3. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8. (Pubitemid 43069790)
4. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64. (Pubitemid 32778199)
5. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52. (Pubitemid 35178607)
6. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
7. 1-antitrypsin deficiency. N Engl J Med 2009;360:2749-57.
8. Kohnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis and treatment. Am J Med 2008;121:3-9.
9. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha (1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-9. (Pubitemid 33152311)
10. Matteson KJ, Ostrer H, Chakravarti A, et al. A study of restriction fragment length polymorphisms at the human alpha-1-antitrypsin locus. Hum Genet 1985;69:263-7. (Pubitemid 15142107)
11. Morgan K, Scobie G, Kalsheker N. The characterization of a mutation of the 3' flanking sequence of the alpha 1-antitrypsin gene commonly associated with chronic obstructive airways disease. Eur J Clin Invest 1992;22:134-7.
12. Kalsheker NA, Watkins GL, Hill S, et al. Independent mutations in the flanking sequence of the alpha-1-antitrypsin gene are associated with chronic obstructive airways disease. Dis Markers 1990;8:151-7. (Pubitemid 20263336)
13. Pillai SG, Ge D, Zhu G, et al; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5: e1000421.
14. Morgan K, Scobie G, Marsters P, et al. Mutation in an alpha1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors. Biochim Biophys Acta 1997;1362:67-76. (Pubitemid 28027113)
15. Talmud PJ, Martin S, Steiner G, et al; Diabetes Atherosclerosis Intervention Study Investigators. Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003;23:644-9. (Pubitemid 36438078)
16. Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol 2005;34:251-6. (Pubitemid 40645308)
17. Pierce M, Tabassum F, Kumari M, et al. Measures of physical health. In: Banks J, Breeze E, Lessof C, et al, eds. Retirement, Health and Relationships of the Older Population in England: The 2004 English Longitudinal Study of Ageing (Wave 2). London: Institute for Fiscal Studies, 2006.
18. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation of quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
19. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20. (Pubitemid 30245950)
20. 1 antitrypsin gene in normal subjects and in patients with pulmonary emphysema. J Med Genet 1987;24:47-51. (Pubitemid 17228871)
21. 1-antitrypsin gene in chronic lung disease. Br Med J 1987;294:1511-14. (Pubitemid 17108387)
22. Poller W, Meisen C, Olek K. DNA polymorphisms of the alpha 1-antitrypsin gene region in patients with chronic obstructive pulmonary disease. Eur J Clin Invest 1990;20:1-7. (Pubitemid 20056266)
23. Smolonska J, Wijmenga C, Postma DS, et al. Meta-analysis on suspected chronic obstructive pulmonary disease genes. Am J Respir Crit Care Med 2009;180:618-31.
24. Morgan K, Scobie G, Kalsheker NA. Point mutation in a 39 flanking sequence of the alpha-1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence. Hum Mol Genet 1993;2:253-7. (Pubitemid 23129084)
25. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:513-20.
26. Dahl M, Tybjaerg-Hansen A, Sillesen H, et al. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha (1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003;107:747-52. (Pubitemid 36222604)
27. Borawski J, Naumnik B, Mysliwiec M. Serum alpha1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients. Ren Fail 2003;25:589-93. (Pubitemid 36944738)
28. 4. Eur Respir J 2000;15:274-80. (Pubitemid 30085952)
29. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha (1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160:1968-75. (Pubitemid 30004705)
30. 1-antitrypsin and leukocyte elastase in infected and noninfected sputum. Am Rev Respir Dis 1979;120:1081-6. (Pubitemid 10218496)
31. Dickson I, Alper CJ. Changes in serum proteinase inhibitor levels following bone surgery. Clin Chim Acta 1974;54:381-5.
32. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
33. Foreman MG, DeMeo DL, Hersh CP, et al. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007;30:1124-30. (Pubitemid 351194759)